What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pulmonary Embolism, Ischemic Stroke
- Main trialPhase 2
- “Phase II trial of TS23”In the company’s words, NCT05408546 on ClinicalTrials.gov
Other drugs for Pulmonary Embolism
- CenvacibartRegeneron · Phase 3
- KinisoquinQuercis Pharma AG · Phase 3
- Recombinant non-immunogenic staphylokinaseSupergene, LLC · Phase 3
- REGN9933Regeneron · Phase 3
- VortosiranRibocure Pharmaceuticals AB · Phase 2
Coming up1
- Jul 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Aug 2026 | Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial | |
| Phase 2Recruiting | Jul 2028 | Strategy for Improving Stroke Treatment Response |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026